American Heart Journal
Volume 141, Issue 6 , Pages 949-956 , June 2001

Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women’s Atorvastatin Trial on Cholesterol (WATCH)

Received 30 September 1999 ,Accepted 16 May 2000.

References 

  1. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham study. Am Heart J. 1987;144:413–419
  2. Fetters JK, Peterson ED, Shaw L, et al.  Sex-specific differences in coronary artery disease risk factors, evaluation and treatment: have they been adequately evaluated?. Am Heart J. 1996;13:796–813
  3. Mosca L, Manson JA, Sutherland SE, et al.  Cardiovascular disease in women. A statement for healthcare professional from the American Heart Association. Circulation. 1997;96:2468–2482
  4. Sacks FM, Maoye LA, Davis BR, et al.  Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation. 1998;97:1446–1452
  5. Longterm Intervention with Pravastatin in Ischemic Disease LIPID Study Group . Prevention of cardiovascular disease and death with pravastatin in patients with coronary disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1354
  6. Kennedy JW, Kaiser GC, Fisher LD, et al.  Clinical and angiographic predictors of operative mortality from the Collaborative Study in Coronary Artery Surgery (CASS). Circulation. 1991;63:793–802
  7. Pedersen TR, Olsson AG, Faergeman O, et al.  Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453–1460
  8. Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel). JAMA. 1993;269:3015–3023
  9. Schrott HL, Bittner V, Vittinghoff E, et al.  Adherence to National Cholesterol Education Program goals in postmenopausal women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study (HERS). JAMA. 1997;277:1281–1286
  10. Davidson M, McKenny J, Stein E, et al.  Comparison of one-year safety and efficacy of atorvastatin versus lovastatin in primary hypercholesterolemia: Atorvastatin Study Group I. Am J Cardiol. 1997;79:1475–1481
  11. Lamon-Fava S, Wilson PWF, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1996;16:1509–1515
  12. Despres JP, Moorjani S, Lupien PJ, et al.  Regional distribution of body fat, plasma lipoproteins and cardiovascular disease. Arteriosclerosis. 1990;10:497–511
  13. Lipid Research Clinics Program . Manual of laboratory operations. Bethesda (MD): National Institutes of Health; 1974;
  14. Converse CA, Skinner ER. Lipoprotein analysis: a practical approach. New York: IRL Press at Oxford University Press; 1992;
  15. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of the low density lipoprotein cholesterol in plasma without the use of the preparative centrifuge. Clin Chem. 1972;18:499–502
  16. Lehmann El. NONPARAMETRICS: statistical methods based on ranks. San Francisco: Holden-Day; 1975;
  17. Winer BJ, Brown DR, Michels KM. Statistical methods in medical research. 2nd ed. New York: McGraw-Hill; 1991;
  18. Lipid Research Clinics Epidemiology Committee . Plasma lipid distribution in selected North American populations: the Lipid Research Clinics Program prevalence study. Circulation. 1979;60:427–439
  19. Brown AS, Bakker-Arkema , Yellin L, et al.  Treating patients with documented atherosclerosis to National Cholesterol Education Program–recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol. 1998;32:665–672
  20. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al.  Treating to meet NCEP-recommended LDL-cholesterol concentrations with atorvastatin, fluvastatin, lovastatin or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract. 1998;47:349–356
  21. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risk by levels and ratios. Ann Intern Med. 1994;121:641–647
  22. Auerbach BJ, Krause BR, Bisgaier CL, et al.  Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin. Atherosclerosis. 1995;117:173–180

☆ Supported by a grant from Parke-Davis Canada and Pfizer Canada. R. M. and J. G. are scientific consultants for Parke-Davis Canada. C. A. and P. M. are employed by Parke-Davis Canada.

☆☆ Reprint requests: Ruth McPherson, MD, PhD, FRCPC, Room H441, University of Ottawa Heart Institute, 40 Ruskin St, Ottawa, Ontario, Canada K1Y 4W7. E-mail: rmcpherson@ottawaheart.ca

PII: S0002-8703(01)59436-3

doi: 10.1067/mhj.2001.115588

American Heart Journal
Volume 141, Issue 6 , Pages 949-956 , June 2001

Article Tools

* Image Usage & Resolution